| [1] |
Sarles H, Sarles JC, Muratore R, et al. Chronic inflammatory sclerosis of the pancreas—an autonomous pancreatic disease?[J]. Am J Dig Dis, 1961(6):688-698.
|
| [2] |
Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. proposal of the concept of autoimmune pancreatitis[J]. Dig Dis Sci, 1995, 40(7):1561-1568.
|
| [3] |
Qureshi A, Ghobrial Y, de Castro J, et al. Autoimmune pancreatitis- what we know and what do we have to know?[J]. Autoimmun Rev, 2021, 20(10):102912.
|
| [4] |
Mack S, Flattet Y, Bichard P, et al. Recent advances in the management of autoimmune pancreatitis in the era of artificial intelligence[J]. World J Gastroenterol, 2022, 28(48):6867-6874.
|
| [5] |
Blaho M, Dítě P, Kunovský L, et al. Autoimmune pancreatitis-an ongoing challenge[J]. Adv Med Sci, 2020, 65(2):403-408.
|
| [6] |
Lee SC, Yang CH, Chang CT, et al. Diagnostic utility of serum IgG4 in autoimmune pancreatitis: an updated comprehensive systematic review and meta-analysis[J]. J Clin Gastroenterol, 2022, 56(9):810-817.
|
| [7] |
van Heerde MJ, Buijs J, Hansen BE, et al. Serum level of Ca19-9 increases ability of IgG4 test to distinguish patients with autoimmune pancreatitis from those with pancreatic carcinoma[J]. Dig Dis Sci, 2014, 59(6):1322-1329.
|
| [8] |
Chen S, Zhang H, Fang F, et al. Characteristics of mass-forming autoimmune pancreatitis commonly misdiagnosed as a malignant tumor[J]. Front Surg, 2023(10):1017621.
|
| [9] |
Minaga K, Watanabe T, Hara A, et al. Identification of serum IFN-α and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease[J]. Sci Rep, 2020, 10(1):14879.
|
| [10] |
Hubers LM, Vos H, Schuurman AR, et al. Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease[J]. Gut, 2018, 67(4):728-735.
|
| [11] |
Shiokawa M, Kodama Y, Sekiguchi K, et al. Laminin 511 is a target antigen in autoimmune pancreatitis[J]. Sci Transl Med, 2018, 10(453):eaaq0997.
|
| [12] |
Perugino CA, AlSalem SB, Mattoo H, et al. Identification of galectin-3 as an autoantigen in patients with IgG4-related disease[J]. J Allergy Clin Immunol, 2019, 143(2):736-745.e6.
|
| [13] |
Akamatsu M, Makino N, Ikeda Y, et al. Specific MAPK-associated microRNAs in serum differentiate pancreatic cancer from autoimmune pancreatitis[J]. PLoS One, 2016, 11(7):e0158669.
|
| [14] |
Li J, Liu F, Fang X, et al. CT radiomics features in differentiation of focal-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma: a propensity score analysis[J]. Acad Radiol, 2022, 29(3):358-366.
|
| [15] |
Wolske KM, Ponnatapura J, Kolokythas O, et al. Chronic pancreatitis or pancreatic tumor? a problem-solving approach[J]. Radiographics, 2019, 39(7):1965-1982.
|
| [16] |
Park S, Chu LC, Hruban RH, et al. Differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma with CT radiomics features[J]. Diagn Interv Imaging, 2020, 101(9):555-564.
|
| [17] |
Ha J, Choi SH, Kim KW, et al. MRI features for differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma: a systematic review and meta-analysis[J]. Dig Liver Dis, 2022, 54(7):849-856.
|
| [18] |
Yoon SB, Jeon TY, Moon SH, et al. Systematic review and meta-analysis of MRI features for differentiating autoimmune pancreatitis from pancreatic adenocarcinoma[J]. Eur Radiol, 2022, 32(10):6691-6701.
|
| [19] |
Kim HJ, Kim YK, Jeong WK, et al. Pancreatic duct "Icicle sign" on MRI for distinguishing autoimmune pancreatitis from pancreatic ductal adenocarcinoma in the proximal pancreas[J]. Eur Radiol, 2015, 25(6):1551-1560.
|
| [20] |
Moon SH, Yoon SB, Jeon TY. ADC values from diffusion-weighted imaging may be lower for autoimmune pancreatitis than for pancreatic ductal adenocarcinoma[J]. Dig Liver Dis, 2022, 54(7):992-993.
|
| [21] |
Sekito T, Ishii Y, Serikawa M, et al. The role of apparent diffusion coefficient value in the diagnosis of localized type 1 autoimmune pancreatitis: differentiation from pancreatic ductal adenocarcinoma and evaluation of response to steroids[J]. Abdom Radiol, 2021, 46(5):2014-2024.
|
| [22] |
Qiu YJ, Zhao GC, Shi SN, et al. Application of dynamic contrast enhanced ultrasound in distinguishing focal-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma[J]. Clin Hemorheol Microcirc, 2022, 81(2):149-161.
|
| [23] |
Bandini G, Moggi Pignone A, Mastrangelo L, et al. Autoimmune pancreatitis: can we truly recognize it? usefulness of contrast-enhanced ultrasonography in two different cases[J]. Eur J Gastroenterol Hepatol, 2022, 34(8):885-886.
|
| [24] |
Suzuki H, Ishikawa T, Ohno E, et al. An initial trial of quantitative evaluation of autoimmune pancreatitis using shear wave elastography and shear wave dispersion in transabdominal ultrasound[J]. Pancreatology, 2021, 21(4):682-687.
|
| [25] |
Ohtani M, Ofuji K, Akazawa Y, et al. Clinical usefulness of [18F]-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography for distinguishing between autoimmune pancreatitis and pancreatic cancer[J]. Pancreas, 2021, 50(7):1014-1019.
|
| [26] |
Cheng MF, Guo YL, Yen RF, et al. Clinical utility of FDG PET/CT in patients with autoimmune pancreatitis: a case-control study[J]. Sci Rep, 2018, 8(1):3651.
|
| [27] |
Wei W, Jia G, Wu Z, et al. A multidomain fusion model of radiomics and deep learning to discriminate between PDAC and AIP based on 18F-FDG PET/CT images[J]. Jpn J Radiol, 2023, 41(4):417-427.
|
| [28] |
Tacelli M, Zaccari P, Petrone MC, et al. Differential EUS findings in focal type 1 autoimmune pancreatitis and pancreatic cancer: a proof-of-concept study[J]. Endosc Ultrasound, 2022, 11(3):216-222.
|
| [29] |
Ishikawa T, Kawashima H, Ohno E, et al. Usefulness of endoscopic ultrasound-guided fine-needle biopsy for the diagnosis of autoimmune pancreatitis using a 22-gauge Franseen needle: a prospective multicenter study[J]. Endoscopy, 2020, 52(11):978-985.
|
| [30] |
Lisotti A, Frazzoni L, Fuccio L, et al. Repeat EUS-FNA of pancreatic masses after nondiagnostic or inconclusive results: systematic review and meta-analysis[J]. Gastrointest Endosc, 2020, 91(6):1234-1241, e4.
|
| [31] |
Yoon SB, Moon SH, Song TJ, et al. Endoscopic ultrasound-guided fine needle aspiration versus biopsy for diagnosis of autoimmune pancreatitis: systematic review and comparative meta-analysis[J]. Dig Endosc, 2021, 33(7):1024-1033.
|
| [32] |
Chhoda A, Rustagi T. EUS-guided needle biopsy for autoimmune pancreatitis[J]. Clin J Gastroenterol, 2020, 13(5):669-677.
|
| [33] |
Gkolfakis P, Crinò SF, Tziatzios G, et al. Comparative diagnostic performance of end-cutting fine-needle biopsy needles for EUS tissue sampling of solid pancreatic masses: a network meta-analysis[J]. Gastrointest Endosc, 2022, 95(6):1067-1077. e15.
|
| [34] |
Löhr JM, Vujasinovic M, Rosendahl J, et al. IgG4-related diseases of the digestive tract[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(3):185-197.
|
| [35] |
Liu B, Tang N, Yao Y, et al. Steroid treatment response combined with serological mark in differentiating type-1 autoimmune pancreatitis from pancreatic cancer[J]. Medicine, 2022, 101(45):e31660.
|
| [36] |
Mitamura K, Arai-Okuda H, Yamamoto Y, et al. Disease activity and response to therapy monitored by [18F]FDG PET/CT using volume-based indices in IgG4-related disease[J]. EJNMMI Res, 2020, 10(1):153.
|
| [37] |
Shiokawa M, Kodama Y, Yoshimura K, et al. Risk of cancer in patients with autoimmune pancreatitis[J]. Am J Gastroenterol, 2013, 108(4):610-617.
|
| [38] |
Macinga P, Pulkertova A, Bajer L, et al. Simultaneous occurrence of autoimmune pancreatitis and pancreatic cancer in patients resected for focal pancreatic mass[J]. World J Gastroenterol, 2017, 23(12):2185-2193.
|
| [39] |
Majumder S, Mohapatra S, Lennon RJ, et al. Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease[J]. Clin Gastroenterol Hepatol, 2018, 16(12):1947-1953.
|
| [40] |
Sano T, Kikuta K, Takikawa T, et al. The M-ANNHEIM-AiP-Activity-Score is useful for predicting relapse in patients with type 1 autoimmune pancreatitis[J]. Pancreatology, 2023, 23(1):112-119.
|
| [41] |
Kubota K, Kamisawa T, Nakazawa T, et al. Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4-sclerosing cholangitis: based on a Japanese nationwide study[J]. J Gastroenterol Hepatol, 2023, 38(4):556-564.
|